Vashishtha Vipin M, Ramachandran V G
Mangla Hospital and Research Center, Bijnor; and *University College of Medical Sciences, New Delhi; India. Correspondence to: Dr Vipin M Vashishtha, Consultant Pediatrician, Mangla Hospital and Research Center, Shakti Chowk, Bijnor, UP 246 701, India.
Indian Pediatr. 2015 Oct;52(10):837-9. doi: 10.1007/s13312-015-0728-5.
Live attenuated SA-14-14-2 vaccine against Japanese encephalitis (JE) was introduced in the routine immunization under Universal Immunization Program in the 181 endemic districts of India. Recently, the Government of India has announced the introduction of one dose of JE vaccine for adults in endemic districts. The policy to mass vaccinate adults has raised several concerns that are discussed in this write-up. Apart from adult vaccination, the continuation of large scale JE vaccination program despite it being a very focal problem, and continued neglect of some other serious public health illnesses have also been highlighted. The issue of lack of authentic data on effectiveness of currently employed SA-14-14-2 JE vaccine has also been discussed.
印度在其181个流行地区的扩大免疫规划下将减毒活SA - 14 - 14 - 2乙型脑炎(乙脑)疫苗纳入常规免疫。最近,印度政府宣布在流行地区为成年人接种一剂乙脑疫苗。大规模为成年人接种疫苗的政策引发了一些在本文中讨论的担忧。除了成人疫苗接种外,尽管乙脑是一个非常局部性的问题,但大规模乙脑疫苗接种计划仍在继续,以及对其他一些严重公共卫生疾病的持续忽视也受到了强调。目前使用的SA - 14 - 14 - 2乙脑疫苗有效性缺乏可靠数据的问题也已被讨论。